Skip to content Skip to footer
Subscribe Now
AstraZeneca and Insitro
NEWS

AstraZeneca and insitro Enter ~$1.5B AI R&D Collaboration for Novel Targets in MASH and Cardiomyopathies

Shots: AstraZeneca has entered a worldwide exclusive research collaboration & licensing agreement with insitro to discover novel targets and advance therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies using AI As per the deal, insitro will receive $40M upfront and is eligible for up to ~$1.46B in discovery, development & commercial milestones, plus single-digit royalties…
8 hours ago

Read more

NEWS

Ocugen and Roots Pharmaceutical Finalize OCU400 Licensing Deal for Retinitis Pigmentosa in MENA Region

Shots: Ocugen has licensed exclusive MENA rights for OCU400, its modifier gene therapy for retinitis pigmentosa, to Roots Pharmaceutical & its strategic partner Al-Dhow International Holding As per the deal, Ocugen will receive ~$4M in upfront fee & development milestones, plus ~$255M in sales milestones, & royalties equaling 22% of OCU400 net sales by Roots…
1 day ago

Read more

NEWS

Vir Biotechnology and Gilead Enter ~$1.87B Deal to Develop PRO-XTEN Dual-Masked T-Cell Engagers for Solid Tumors

Shots: Vir has entered into a collaboration & license agreement with Gilead to discover & engineer 3 novel PRO-XTENdual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens  As per the deal, Vir will discover, design, & optimize three PRO-XTEN dual-masked TCE candidates, while Gilead will hold exclusive rights to nominate & advance them,…
1 day ago

Read more

NEWS

Rona Therapeutics and Roche Partner to Advance an Obesity Therapy in a ~$1.16B Deal

Shots: Rona Therapeutics has granted Roche an exclusive worldwide license to Rona’s RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's extrahepatic delivery platform As per the deal, Rona will receive ~$100M in upfront & near-term milestone payments, plus ~$1.06B in development, regulatory & commercial milestone payments, as well as tiered royalties on…
3 days ago

Read more

NEWS

Abogen and Novartis Partner to Advance RNA-Encoded Therapeutics in $575M Upfront, $7.2B Milestone Deal

Shots: Abogen has entered into a licensing & option agreement, granting Novartis an exclusive worldwide license to ABO2203, as well as options to exclusively license other potential programs that leverage Abogen's RNA platform As per the deal, Abogen will receive ~$575M upfront &, if all options on all programs are exercised, Abogen will gain ~$7.2B…
October 5, 2026

Read more

NEWS

Tolerance Bio and Tanabe Pharma Partner for MT-2990 in Deal With Up to $560M in Milestones

Shots: Tolerance Bio has entered into an exclusive license agreement with Tanabe Pharma for MT-2990, an anti-IL-33 monoclonal antibody, across all indications Tanabe Pharma has granted Tolerance Bio worldwide development & manufacturing rights, and ex-Japan exclusive commercialization rights for MT-2990 (TLB-33), while Tanabe will retain commercialization rights in Japan As per the deal, Tanabe will…
September 30, 2026

Read more

NEWS

Amberstone and Henlius Partner to Develop Conditionally Activated T-Cell Engagers for Solid Tumors

Shots: Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization…
September 25, 2026

Read more

Load more